Evidence map›Paper›PMID 40342411›Full record

ArticleFrontiers in immunology2025

SAPrIm 2.0: a semi-automated protocol for mid-throughput soluble HLA immunopeptidomics.

Erwin Tanuwidjaya, Terry C C Lim Kam Sian, Joel R Steele, Gabriel Goncalves, Isaac B Woodhouse, Janet Chang, Joshua D Ooi, Ralf B Schittenhelm, Pouya Faridi

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Erwin TanuwidjayaDepartment of Medicine, School of Clinical Science, Faculty of Medicine, Nursing & Health Science, Monash University, Clayton, VIC, Australia.
Terry C C Lim Kam SianDepartment of Medicine, School of Clinical Science, Faculty of Medicine, Nursing & Health Science, Monash University, Clayton, VIC, Australia.
Joel R SteeleMonash Proteomics & Metabolomics Platform, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Gabriel GoncalvesDepartment of Medicine, School of Clinical Science, Faculty of Medicine, Nursing & Health Science, Monash University, Clayton, VIC, Australia.
Isaac B WoodhouseDepartment of Medicine, School of Clinical Science, Faculty of Medicine, Nursing & Health Science, Monash University, Clayton, VIC, Australia.
Janet ChangDepartment of Medicine, School of Clinical Science, Faculty of Medicine, Nursing & Health Science, Monash University, Clayton, VIC, Australia.
Joshua D OoiDepartment of Medicine, School of Clinical Science, Faculty of Medicine, Nursing & Health Science, Monash University, Clayton, VIC, Australia.
Ralf B SchittenhelmMonash Proteomics & Metabolomics Platform, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Pouya FaridiDepartment of Medicine, School of Clinical Science, Faculty of Medicine, Nursing & Health Science, Monash University, Clayton, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human leukocyte antigen (HLA) molecules are pivotal in guiding human adaptive immune responses through their presentation of peptide ligands, collectively known as the immunopeptidome. This process is central to the development of cancer immunotherapies, such as vaccines and T-cell therapies. Profiling the immunopeptidome from plasma and other biofluids has gained increasing traction, as it offers a minimally invasive approach for monitoring disease states and immune responses toward cancer therapy. Here we present the second iteration of SAPrIm, a refined immunopeptidomics tool optimized for soluble HLA analysis. It can process up to 12 samples per batch within a day. In this plasma-focused iteration, we identified approximately 1,200 to 4,000 immunopeptides from 100 µL to 1 mL of plasma, demonstrating high reproducibility across technical replicates, biological replicates, and inter-day analyses. This robust reproducibility highlights the method's strong potential for reliable relative quantification of immunopeptides in plasma-based studies. This workflow is positioned to advance the field of immunopeptidomics by enabling efficient plasma-based comparative analyses and mid-size cohort studies.

Indexed as

HLA AntigensPeptidesProteomicsHumansReproducibility of ResultsHLA AntigensPeptidesHLAimmunopeptidomicsmass spectrometryMHCplasma immunopeptidomicsSAPrImsHLAsoluble HLA

Identifiers

PMID40342411
PMCPMC12058715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.